الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 88 |  |  |
| | | from | 88 | | |
Abstract
Acquired haemophilia is a potentially life threatening bleeding
disorder caused by the development of autoantibodies against
coagulation factor VIII.
In around half of patients, an underlying disorder is associated with
AHA; the remaining cases are idiopathic.
AHA presents with bleeding, ranging from mild to life threatening,
in patients with no personal or family bleeding history.
Diagnosis involves an isolated prolongation of the activated partial
thromboplastin time, without correction in mixing studies, low
FVIII activity levels and evidence of a FVIII inhibitor.
As AHA is rare, a lack of familiarity of the condition may result in
delayed diagnosis
Prompt hemostatic control is required to reduce morbidity and
mortality. Bypassing agents (recombinant activated factor VII or
activated prothrombin complex concentrates) can be used to
control acute bleeding
Immunosuppression is necessary to eradicate the inhibitor.
Prognosis in AHA depends on presence of comorbidities, on
severity of bleeding and on the time to diagnosis and initiation of
appropriate anti hemorrhagic and immunosuppressive treatment.
As clinical trials in this rare and heterogeneous disease are difficult,
current evidence comes from observational studies, including
registries.